Table 2.
Correlation between serum concentrations of C4 and cholesterol parameters in patients with NASH treated with PGBF.
|
Baseline concentrations |
ρ∗ |
p value† |
| C4 vs. ApoA1 | 0.40 | 0.000621 |
| C4 vs. HDL cholesterol | 0.31 | 0.00998 |
| C4 vs. total cholesterol | 0.29 | 0.0164 |
| C4 vs. LDL cholesterol | 0.19 | 0.110 |
| C4 vs. LDL/HDL ratio |
-0.04 |
0.687 |
|
Percentage change from baseline to Day 112 |
ρ∗ |
p value† |
| % C4 vs. % LDL/HDL ratio | -0.41 | 0.000858 |
| % C4 vs. % ApoA1 | 0.40 | 0.002070 |
| % C4 vs. % HDL | 0.30 | 0.016500 |
| % C4 vs. % LDL | -0.08 | 0.541000 |
| % C4 vs. % total cholesterol | 0.07 | 0.590000 |
| % DCA vs. % LDL/HDL ratio | 0.44 | 0.000328 |
| % TDCA vs. % LDL/HDL ratio | 0.39 | 0.001900 |
| % GDCA vs. % LDL/HDL ratio | 0.31 | 0.015100 |
| % total DCA + conjugates vs. % LDL/HDL ratio | 0.41 | 0.001050 |
ApoA1, apolipoprotein A1; C4, 7α-hydroxy-4-cholesten-3-one; DCA, deoxycholic acid; GDCA, glyco-deoxycholic acid; NASH, non-alcoholic steatohepatitis; PGBF, pegbelfermin; TDCA, tauro-deoxycholic acid.
∗
Spearman correlation was calculated using Spotfire software (TIBCO Software Inc., Palo Alto, CA, USA). Values >0.3 were considered significant.
†
Unadjusted p values were calculated using Spotfire software. Values <0.05 were considered significant.